Cargando…
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
BACKGROUND: The drug–drug interaction between rifampicin and dolutegravir can be overcome by supplemental dolutegravir dosing, which is difficult to implement in high-burden settings. We aimed to test whether virological outcomes with standard-dose dolutegravir-based antiretroviral therapy (ART) are...
Autores principales: | Griesel, Rulan, Zhao, Ying, Simmons, Bryony, Omar, Zaayid, Wiesner, Lubbe, Keene, Claire M, Hill, Andrew M, Meintjes, Graeme, Maartens, Gary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322729/ https://www.ncbi.nlm.nih.gov/pubmed/37230101 http://dx.doi.org/10.1016/S2352-3018(23)00081-4 |
Ejemplares similares
-
Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial
por: Griesel, Rulan, et al.
Publicado: (2021) -
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023) -
Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023) -
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021) -
Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)